REGULATED PRESS RELEASE published on 06/03/2024 at 17:45, 3 months 16 days ago imerys-31-05-2024-communique-capital-droits-de-vote-au-30-avril-2024 Imerys est le leader mondial des spécialités minérales pour l'industrie avec un chiffre d'affaires de 3,8 milliards d'euros en 2023. Le Groupe propose des solutions à haute valeur ajoutée pour divers secteurs en croissance Chiffre D'affaires Imerys Spécialités Minérales Solutions À Haute Valeur Ajoutée Secteurs En Croissance
BRIEF published on 05/15/2024 at 17:50, 4 months 4 days ago Imerys Announces Major Climate Transition Plan for 2030 Sustainability Environmental Goals Climate Transition Plan Imerys GHG Emissions Reduction
BRIEF published on 05/15/2024 at 17:50, 4 months 4 days ago Imerys annonce un plan de transition climatique ambitieux pour 2030 Développement Durable Réduction Des Émissions Imerys Plan De Transition Climatique Économie Bas Carbone
REGULATED PRESS RELEASE published on 05/15/2024 at 17:45, 4 months 4 days ago Press-Release-Imerys-unveils-an-ambitious-Climate-Transition-Plan Imerys unveils comprehensive Climate Transition Plan approved by the Board of Directors, demonstrating commitment to combat climate change and integrate climate considerations into core business operations Greenhouse Gas Emissions Science Based Targets Initiative Climate Transition Plan Imerys GHG Emissions
REGULATED PRESS RELEASE published on 05/15/2024 at 17:45, 4 months 4 days ago Communique-Imerys-devoile-un-Plan-de-Transition-Climatique-ambitieux Imerys dévoile son Plan de Transition Climatique approuvé par le Conseil d'Administration pour réduire les émissions de GES et soutenir la durabilité environnementale Science Based Targets Initiative Réduction Des Émissions Imerys Plan De Transition Climatique Durabilité Environnementale
BRIEF published on 05/14/2024 at 20:50, 4 months 5 days ago Imerys Shareholders Approve Key Resolutions in 2024 General Meeting Financial Statements Dividend Imerys Board Appointments Shareholders Meeting
BRIEF published on 05/14/2024 at 20:50, 4 months 5 days ago Compte-rendu de l'Assemblée Générale Ordinaire d'Imerys du 14 mai 2024 Gouvernance Assemblée Générale Dividende Comptes Annuels Imerys
BRIEF published on 05/14/2024 at 20:49, 4 months 5 days ago IMERYS Annonce la Publication de son Rapport sur les Paiements aux Gouvernements Développement Durable Rapport Financier Imerys Industrie Minérale Paiements Gouvernementaux
BRIEF published on 05/14/2024 at 20:49, 4 months 5 days ago Imerys Reports Payments Made to Governments for Regulatory Compliance Sustainable Construction Energy Transition Financial Transparency Imerys Government Payments
REGULATED PRESS RELEASE published on 05/14/2024 at 20:45, 4 months 5 days ago imerys-14-05-2024-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-14-mai-2024 (final) L'Assemblée Générale d'Imerys approuve les comptes 2023, dividendes et gouvernance. Programme de rachat d'actions renouvelé. Agenda financier annoncé Rachat D'actions Assemblée Générale Dividende Agenda Financier Imerys
Published on 09/20/2024 at 02:00, 7 hours 20 minutes ago Academy of Math and Science Celebrates Hispanic Heritage Month
Published on 09/19/2024 at 23:15, 10 hours 5 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 10 hours 20 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/20/2024 at 09:01, 19 minutes ago Original-Research: THE NAGA GROUP AG (von NuWays AG): BUY
Published on 09/20/2024 at 07:30, 1 hour 50 minutes ago XTPL with PLN 5.6 million of commercial sales in H1 2024 and progress on industrial projects - press release
Published on 09/20/2024 at 07:00, 2 hours 20 minutes ago Mister Spex SE: Extraordinary General Meeting adopts all resolutions as proposed by the Company’s Boards
Published on 09/20/2024 at 06:26, 2 hours 54 minutes ago Original-Research: www.warimpex.com (von East Value Research GmbH ):
Published on 09/20/2024 at 08:00, 1 hour 20 minutes ago MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai clinique de phase 2a pour le traitement de la maladie d’Alzheimer avec le NanoLIthium